IMW 2019 | MRD as a prognostic tool in amyloidosis

Surbhi Sidana

Surbhi Sidana, MBBS Mayo Clinic, Rochester, MN, discusses preliminary data regarding the role of measurable residual disease (MRD) as a prognostic tool in light-chain amyloidosis, drawing on results from studies at the Mayo clinic. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video